AVROBIO, Inc. (AVRO)

1.2300 0.0000 (0.00%) 市場開市。 截至 01:13PM EDT。

AVROBIO, Inc.

100 Technology Square
Sixth Floor
Cambridge, MA 02139
United States
(617) 914-8420
https://www.avrobio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 13

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Erik John Ostrowski M.B.A.	President, Interim CEO, CFO & Treasurer	1.25M	無	1972
Dr. Azadeh Golipour Ph.D.	Chief Technology Officer	1.01M	無	1980
Dr. Essra Ridha FFPM, M.D.	Chief Medical Officer	1.12M	無	1983
Mr. Jeffrey Medin Ph.D.	Scientific Founder	無	無	無
Mr. Steven N. Avruch J.D.	Chief Legal Officer & Secretary	506.68k	無	1962
Mr. Scott Gottesman	Vice President of Human Resource	無	無	無
Ms. Kirsten Dupuis	Chief of Staff	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年5月1日 止，AVROBIO, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：8；董事會：7；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。